Singular Health GroupASX:SHG 30 3-Year RORE % is 3.61 as of Dec. 2025. GuruFocus rates ASX:SHG with a GF Score™ of 30/100 and a GF Value™ of A$0.11 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Singular Health Group ranks better than 53.72% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Singular Health Group's 3-Year RORE % for the quarter that ended in Dec. 2025 was 3.61%.
The industry rank for Singular Health Group's 3-Year RORE % or its related term are showing as below:
ASX:SHG's 3-Year RORE % is ranked better than 53.72% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: -0.32
vs ASX:SHG: 3.61
Singular Health Group (ASX:SHG) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Singular Health Group 3-Year RORE % Related Terms
Singular Health Group 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Singular Health Group's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SHG vs VEEV, BTSG, TEM: 3-Year RORE % Comparison
For the Health Information Services subindustry, Singular Health Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Singular Health Group 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Singular Health Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Singular Health Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Singular Health Group (ASX:SHG) has a 3-Year RORE % of 3.61 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Singular Health Group and its competitors. According to the industry distribution chart, Singular Health Group ranks #280 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 46.3%.
Is Singular Health Group's 3-Year RORE % too high?
Singular Health Group's current 3-Year RORE % is 3.61. Based on the distribution chart, Singular Health Group ranks #280 out of 605 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Singular Health Group has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Singular Health Group's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Singular Health Group ranks #280 out of 605 companies for 3-Year RORE %. This puts Singular Health Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
A good 3-Year RORE % depends on the Healthcare Providers & Services industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Singular Health Group and its competitors. Singular Health Group's current 3-Year RORE % is 3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singular Health Group stock overvalued right now?
Based on GuruFocus' analysis, Singular Health Group (ASX:SHG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.11, compared to a current price of A$0.21 — trading 90.9% above its estimated fair value. The current 3-Year RORE % is 3.61. Singular Health Group's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Singular Health Group (ASX:SHG), the current 3-Year RORE % is 3.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Singular Health Group (ASX:SHG) Overvalued in 2026?
Based on GuruFocus' analysis, Singular Health Group stock appears to be overvalued.
The current stock price of A$0.21 is trading 90.9% above its estimated GF Value™ of A$0.11.
GuruFocus considers Singular Health Group to be Significantly Overvalued.
Key valuation signals for ASX:SHG:
3-Year RORE %: 3.61
GF Value™: A$0.11 vs. price of A$0.21 (90.9% above fair value)
No single metric tells the full story. See the ASX:SHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Singular Health Group Ltd provides medical software solutions. The company's business segment is the provision of Volume Rendering Platform (VRP) software, providing 3D printing services and 3D machine sales. It operates in one segment, which is the provision and development of medical technology within Australia.
30GF Score
Get the complete analysis for ASX:SHG
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SHG has been successfully added to your 
